Preliminary evaluation of the in vitro release and in vivo absorption in rabbits of the modified-release dosage forms

Drug Development and Industrial Pharmacy

Volumn 39, Issue 6, 2013, Pages 889-900

  Petrovic, Aleksandra A ^a   Petricevic, Sasa M ^a   Ristic, Slavica M ^a   Ibric, Svetlana R ^b   Simic, Slobodanka S ^a   Djuric, Zorica R ^b   Popovic, Radmila B ^a  

^a Galenika Ad   (Serbia)

^b Faculty of Pharmacy   (Serbia)

Author keywords

Absorption in vivo; Aminophylline; in vitro dissolution; in vitro in vivo correlation; Modified release tablets; Rabbit

Indexed keywords

AMINOPHYLLINE; CARBOMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RABBIT; TABLET;

ADMINISTRATION, ORAL; AMINOPHYLLINE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG EVALUATION, PRECLINICAL; INTESTINAL ABSORPTION; RABBITS; TABLETS;

EID: 84877010684     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.713364     Document Type: Article

References (62)

1. Furlanetto S, Cirri M, Maestrelli F, Corti G, Mura P. (2006). Study of formulation variables influencing the drug release rate from matrix tablets by experimental design. Eur J Pharm Biopharm, 62:77-84.
2. USP-30; NF-25. (2007). The United States Pharmacopeia/The National Formulary. Rockville, USA: United States Pharmacopeial Convention Inc.
3. EMEA/CPMP. (2000). Note for Guidance on quality of modified release products: A. oral dosage forms; B: transdermal dosage forms.
4. FDA/CDER. (1997). Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of InVitro/InVivo Correlations.
5. Emami J. (2006). In vitro - in vivo correlation: from theory to applications. J Pharm Pharm Sci, 9:169-189.
6. Qui Y. (2009). Chapter 17: In vitro - In vivo correlations: Fundamentals, Development Consideration, and Application. In: Qui Z, Chen Z, Zhang G, eds. Developing Solid Oral Dosage Forms, Pharmaceutical Theory and Practice, first edition. USA: Elsevier, 379-406.
7. Wagner JG, Nelson E. (1964). Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci, 53:1392-1403.
8. Souliman S, Blanquet S, Beyssac E, Cardot JM. (2006). A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. Eur J Pharm Sci, 27:72-79.
9. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HN. (2007). In-vitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations: a pharmacoscintigraphic study in the beagle dog. Eur J Pharm Biopharm, 67:515-523.
10. Kararli TT. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos, 16:351-380.
11. Ikegami K, Tagawa K, Osawa T. (2006). Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and gottingen minipigs. J Pharm Sci, 95:1888-1895.
12. Zhou H, Seitz K. (2009). Chapter 16: In vivo Evaluation of Oral Dosage Form Performance - Animal Species Selection. In: Qui Z, Chen Z, Zhang G eds. Developing Solid Oral Dosage Forms, Pharmaceutical Theory and Practice, first edition. USA: Elsevier, 366-368.
13. He H, Yang R, Tang X. (2010). In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm, 36:681-687.
14. Yin L-F, Huang S-J, Jiang S-G, Zhao C-J, Pei Z-Q. (2011). In vitro and in vivo evaluation of levofloxacin sustained-release capsules. Drug Dev Ind Pharm, 36:681-687.
15. Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. (2004). Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm, 58:607-614.
16. Yu Z, Schwartz JB, Sugita ET. (1996). Theophylline controlledrelease formulations: in vivo-in vitro correlations. Biopharm Drug Dispos, 17:259-272.
17. Lobenberg R, Kim JS, Amidon GL. (2005). Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm, 60:17-23.
18. Hayashi T, Kanbe H, Okada M, Kawase I, Ikeda Y, Onuki Y et al. (2007). In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. Int J Pharm, 341:105-113.
19. Chiou WL, Jeong HY, Chung SM, Wu TC. (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res, 17:135-140.
20. Davis SS, Illum L, Hinchcliffe M. (2001). Gastrointestinal transit of dosage forms in the pig. J Pharm Pharmacol, 53:33-39.
21. Sakuma S, Ogura R, Masaoka Y, Kataoka M, Tanno FK, Kokubo H et al. (2009). Correlation between in vitro dissolution profiles from enteric-coated dosage forms and in vivo absorption in rats for high-solubility and high-permeability model drugs. J Pharm Sci, 98:4141-4152.
22. El-Yazigi A, Sawchuk RJ. (1981). Theophylline absorption and disposition in rabbits: oral, intravenous, and concentrationdependent kinetic studies. J Pharm Sci, 70:452-456.
23. Musko Z, Pintye-Hodi K, Gaspar R, Pintye J, Szabo-Revesz P, Eros I et al. (2001). Study of in vitro and in vivo dissolution of theophylline from film-coated pellets. Eur J Pharm Biopharm, 51:143-146.
24. Zhu XJ, Yuan W, Li P, Liu X, He JQ. (2010). Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. Drug Dev Ind Pharm, 36:1463-1468.
25. Tamilvanan S, Venkatesh Babu R, Nappinai A, Sivaramakrishnan G. (2011). In vitro and in vivo evaluation of hydrophilic and hydrophobic polymers-based nicorandil-loaded peroral tablet compared with its once-daily commercial sustained-release tablet. Drug Dev Ind Pharm, 37:436-445.
26. Varshosaz J, Ghafghazi T, Raisi A, Falamarzian M. (2000). Biopharmaceutical characterization of oral theophylline and aminophylline tablets. Quantitative correlation between dissolution and bioavailability studies. Eur J Pharm Biopharm, 50:301-306.
27. Petrovic A, Ibric S, Trajkovic S, Popovic R, Djuric Z, Popadic D. (2009). An investigation into effects of in vitro test condition on the release properties of theophylline from HPMC matrices using factorial design. Arch Pharm Res, 32:1087-1096.
28. Petrovic A, Cvetkovic N, Ibric S, Trajkovic S, Djuric Z, Popadic D et al. (2009). Application of mixture experimental design in the formulation and optimization of matrix tablets containing carbomer and hydroxy- propylmethylcellulose. Arch Pharm Res, 32:1767-1774.
29. Petrović A, Popović R, Djurić Z, Trajković S, Dželetović D, Popadić D. (2004). An in vitro comparison of controlled release aminophylline tablets, Proc. 4 th International Meeting on Pharmaceutics, Biopharmaceutics, Pharmaceutical Technology, Nurberg 15/18 Marc 2004, ADRITELF/APGI/APV Abstract book 593-594.
30. Petrović A, Trajković S, Ibrić S, Popadić D, Cvetković N, Djurić Z. (2006). Comparative evaluation of in vitro drug release from comercially available aminophylline sustained release products by model-dependent and independent methods, 33th international Symposium on Controlled Release of Bioactive Materials, Vien 22/25, July 2006, Abstract book on CD PO-269.
31. Donovan J, Brown P. (2006). Blood collection. In: Current Protocols in Immunology. USA: John Wiley & Sons. Inc, 1.7.1-1.7.9.
32. Yuksel A. (2000). Comparison of in vitro dissolution profiles by Anova based model dependent and independent methods. Int J Pharm, 209:57-67.
33. Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123-133.
34. Siepmann J, Peppas NA. (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev, 48:139-157.
35. Kiortsis S, Kachrimanis K, Broussali T, Malamataris S. (2005). Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. Eur J Pharm Biopharm, 59:73-83.
36. Ritger PL, Peppas NS. (1987). A simple equation for disposition of solute release II: Fickian and anomalous release from swellable devices. J Control Release, 5:37-42.
37. Cardot J-M. (2007). Introduction to the in vitro - In vivo Correlation (IVIVC). Post-Conference Workshop organized by Informa Life Sciences, 25 May, Budapest.
38. Bourne DWA. (2002).Chapter 3: Pharmacokinetics. In: Banker S, Rhodes C eds. Modern Pharmaceutics 4th edition. NewYork: Marcel Dekker Inc, 77-101.
39. Shah HJ, Subbaiah G, Patel DM, Patel CN. (2009). In vitroin vivo correlation of modified release dosage form of lamotrigine. Biopharm Drug Dispos, 30:524-531.
40. el-Yazigi A, Sawchuk RJ. (1985). In vitro-in vivo correlation and dissolution studies with oral theophylline dosage forms. J Pharm Sci, 74:161-164.
41. Tse FL, Szeto DW. (1982). Theophylline bioavailability in the dog. J Pharm Sci, 71:1301-1303.
42. Torrent J, Izquierdo I, Barbanoj MJ, Obach R, Nomen M, Jane F. (1988). Theophylline pharmacokinetics following single and repeated administration of slow-release capsules. Eur J Drug Metab Pharmacokinet, 3:225-230.
43. Sabnis S, Adeyeye CM. (1998). Controlled-release hydrophilic tablets for individualized theophylline therapy. Drug Dev Ind Pharm, 25:187-196.
44. Bendas ER. (2009). Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride. Arch Pharm Res, 32:1317-1329.
45. Delvadia PR, Barr WH, Karnes HT. (2012). A biorelevant in vitro release/permeation system for oral transmucosal dosage forms. Int J Pharm, 430:104-113.
46. Gohel M, Delvadia RR, Parikh DC, Zinzuwadia MM, Soni CD, et al. (2005) Simplified Mathematical Approach for Back Calculation in Wagner-Nelson Method. Pharm Rev 3(2). http:// www.pharmainfo.net/reviews/simplified- mathematicalapproach- back-calculation-wagner-nelson-method.
47. Aronson JK, Hardman M, Reynolds DJ. (1992). ABC of monitoring drug therapy. Theophylline. BMJ, 305:1355-1358.
48. Wagner JG. (1986). Estimation of theophylline absorption rate by means of the Wagner-Nelson equation. J Allergy Clin Immunol, 78:681-688.
49. Milavetz G, Vaughan LM, Weinberger MM. (1987). Stability of theophylline elimination rate. Clin Pharmacol Ther, 41:388-391.
50. Gohel MC, Jani GK, Amin AF, Patel KV, Gupta SV. (1997). Application of classical experimental design for the development of theophylline microspheres. J Control Release, 45:265-271.
51. EMEA, Committee for veterinary medicinal product. Diprophylline - Summary Report. EMEA/MRL/386/98-FINAL. April 1998.
52. CDER (Center for Drug Evaluation and Research). (1997). Guidance for Industrial Extended Release Oral Dosage Forms: Development, Evaluation and Application of in vitro/In vivo Correlation. Rockville, MD: Food and Drug Administration.
53. Musko Z, Pintye-Hodi K, Gaspar R, Pintye J, Szabo-Revesz P, Eros I, Falkay G. (2001). Study of in vitro and in vivo dissolution of theophylline from film-coated pellets. Eur J Pharm Biopharm, 51:143-146.
54. Puchun L, Tzuchi R, Yihong Q. (2005). Chapter 4: Diffusion Controlled Drug Delivery Systems. In: Xiaoling L, Bhaskara R, eds. Design of Controlled Release Drug Delivery Systems. USA:McGraw-Hill Companies, Inc, 107-138.
55. Wong LP, Gilligan CA, Li-Wan PA. (1992). Preparation and characterization of sustained-release ibuprofen-cetostearyl alcohol spheres. Int J Pharm, 83:95-114.
56. Quadir MA, Rahman MS, Karim MZ, Akter S, Awkat MT, Reza MS. (2003). Evaluation of hydrophobic materials as matrices for controlled-release drug delivery. Pak J Pharm Sci, 16:17-28.
57. Islam S, Khan F, Jalil R. (2010). Sustained Release Theophylline Matrix Tablets Prepared by Direct compression I: Effect of Hydrophobic Excipients. Ban Pharm J, 13: 3-8.
58. Dunne A, OHara T, Devane J. (1997). Level A in vivo-in vitro correlation: nonlinear models and statistical methodology. J Pharm Sci, 86:1245-1249.
59. Parojcic J, Ibric S, Djuric Z, Jovanovic M, Corrigan OI. (2007). An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur J Pharm Sci, 30:264-272.
60. Scheubel E, Adamy L, Hoffart V, Cardot JM. (2010). Selection of the most suitable dissolution method for an extended release formulation based on IVIVC level A obtained on cynomolgus monkey. Drug Dev Ind Pharm, 36:1320-1329.
61. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res, 19:921-925.
62. Nandy BC, Roy S, Mayumder B, Meena K, Ahuja D, et al. (2011). In vitro-in vivo Correlation: Application in pharmaceutical development of various dosage forms. J Chem Pharm Res, 3:550-564.